MedTrace Logo

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

NCT00165490 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2014-11-10

No results posted yet for this study

Summary

The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.

Conditions

  • Adenocarcinoma of Esophagus
  • Squamous Cell Carcinoma of Esophagus

Interventions

DRUG

Cetuximab

Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.

DRUG

Cisplatin

Given once per week on weeks 1, 2, 4,and 5.

DRUG

Irinotecan

Given once per week on weeks 1, 2, 4,and 5.

DEVICE

Radiation therapy

Once daily for 28 treatments (5 1/2 weeks)

PROCEDURE

Surgery

Surgery performed 4-8 weeks after chemoradiation therapy.

Sponsors & Collaborators

Principal Investigators

  • Peter Enzinger, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165490 on ClinicalTrials.gov